

Date: 14/11/2022

To  
Dept. of Corporate Services,  
BSE Limited,  
Floor 25, P J Tower, Dalal Street,  
Mumbai - 400001.

**Scrip code: 526445**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting.**

**Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Please refer our letter dated November 05, 2022 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In continuation, we wish to inform that at the meeting of Board of Directors held today i.e., on **November 14, 2022**, the Directors have *inter-alia* considered and approved the following amongst other subject matters:

- Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report of the Company for the quarter and half year ended September 30, 2022 (Q2), pursuant to Regulation 33 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Investment of Rs.30,00,000 (Thirty Lakhs only) in the equity shares of Matrix Boilers Private Limited in order to acquire it as Subsidiary of our company.
- Loan of Rs.10,00,00,000 (Ten Crores only) to meet working capital requirement and other financial commitments of Matrix Biologics Private Limited.

We, herewith, have attached the copy of the unaudited financial results (standalone and consolidated) for the quarter ended September 30, 2022 along with the Limited Review Report for the said period.

The Board Meeting commenced at 6:45 p.m. and concluded at 7:20 p.m. The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website [www.indrayani.com](http://www.indrayani.com) and also on BSE website [www.bseindia.com](http://www.bseindia.com).

We request you to kindly take the same on your records.

Thanking you.

Yours faithfully,

**For Indrayani Biotech Limited**



**Kasiraman Sayee Sundar**  
Managing Director  
DIN: 01295584





**VENKATESH & CO**

Chartered Accountants

**Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015**

To  
The Board of Directors  
**Indrayani Biotech Limited**

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30<sup>th</sup> September, 2022** and for the period from **1<sup>st</sup> July 2022 to 30<sup>th</sup> September 2022** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **30<sup>th</sup> September, 2021** and corresponding period from 1<sup>st</sup> July 2021 to 30<sup>th</sup> September 2021 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the unaudited results of the following entities:

- i. HSL Agri Solutions Limited – Subsidiary
- ii. IBL Healthcare Limited – Subsidiary
- iii. Dindigul Farm Product Private Limited - Subsidiary
- iv. IBL Thiruvannamalai LLP - Step down Subsidiary
- v. HSL Prime Properties Private Limited - Subsidiary



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai 600 017.

Telefax : 2814 4763/64/65/66 Email : venkateshandco@gmail.com



Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


We did not review the financial statement / financial information of **4 Subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 30<sup>th</sup> September, 2022 reflects total revenues of **₹ 5,013.08 Lakhs**, total comprehensive profit / (loss) of **₹ 454.76 Lakhs** for the period ended on that date in respect of **M/s. IBL Thiruvannamalai LLP** (stepdown subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of **₹ 9.63 Lakhs**, total net profit / (Loss) after tax of **₹ (4.06) Lakhs** for the period ended on that date, as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

**for Venkatesh & Co**

Chartered Accountants

FRN : 004536S



**CA Dasaraty V**

Partner

M No : 026336



UDIN: 22026336BDBSVG2301

Chennai, 14<sup>th</sup> November 2022

**INDRAYANI BIOTECH LIMITED**

Regd. Office :

BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032


**STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2022**

Rs. In Lakhs

SR No	PARTICULARS	CONSOLIDATED					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2022	30-06-2022	30-09-2021	30-09-2022	30-09-2021	31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	(a) Net Sales/Revenue from Operations	4,205.30	2,563.21	1,485.24	6,768.51	2,916.46	6,157.18
	(b) Other Income	196.41	39.39	3.70	235.80	6.26	22.08
	<b>Total Income from Operations</b>	<b>4,401.70</b>	<b>2,602.61</b>	<b>1,488.94</b>	<b>7,004.31</b>	<b>2,922.72</b>	<b>6,179.26</b>
2	<b>Expenses</b>						
	(a) Cost of Materials consumed	3,022.79	1,615.76	969.90	4,638.55	1,910.58	4,104.29
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(281.94)		-	(281.94)		
	(c) Employee benefits expenses	504.81	438.64	279.24	943.45	573.95	1,021.64
	(d) Finance Costs	115.16	96.95	52.90	212.11	85.14	187.97
	(e) Depreciation and amortisation expense	74.96	66.41	10.72	141.37	21.38	65.94
	(f) Other expenses	415.20	206.11	72.02	621.31	164.21	354.23
	<b>Total Expenses</b>	<b>3,850.99</b>	<b>2,423.86</b>	<b>1,384.78</b>	<b>6,274.85</b>	<b>2,755.26</b>	<b>5,734.07</b>
	<b>Total profit / (Loss) before exceptional items and tax</b>	<b>550.71</b>	<b>178.75</b>	<b>104.16</b>	<b>729.46</b>	<b>167.46</b>	<b>445.19</b>
3	Exceptional Items			-		1.06	
4	Add: Share of Profit In Associates	(25.00)		(0.14)	(25.00)		
5	<b>Total profit / (Loss) before tax</b>	<b>525.71</b>	<b>178.75</b>	<b>104.02</b>	<b>704.46</b>	<b>168.52</b>	<b>445.19</b>
6	<b>Total profit / (Loss) before tax</b>						
7	<b>Tax Expenses</b>		(0.16)		-		1.24
	Current Tax						
	Deferred Tax						
	<b>Total Tax Expenses</b>						
8	<b>Net Profit Loss for the period from continuing operations</b>	<b>525.71</b>	<b>178.91</b>	<b>104.02</b>	<b>704.46</b>	<b>168.52</b>	<b>443.95</b>
9	<b>Profit (loss) from discontinued operations before tax</b>						
10	<b>Tax expense of discontinued operations</b>						
11	<b>Net profit (loss) from discontinued operation after tax</b>						
12	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>						
13	<b>Total profit (loss) for period</b>	<b>525.71</b>	<b>178.91</b>	<b>104.02</b>	<b>704.46</b>	<b>168.52</b>	<b>443.95</b>
14	<b>Other comprehensive income net of taxes</b>						
15	<b>Total Comprehensive income for the period attributable to</b>						
	Comprehensive income for the period attributable to owners of parent	23.18	161.46	106.42	184.64	173.66	442.75
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests	502.38	17.44	(2.73)	519.82	(5.13)	1.20
16	<b>Details of equity share capital</b>						
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital(Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
17	<b>Details of debt securities</b>						
	Paid-up debt capital						
	Face value of debt securities						

For INDRAYANI BIOTECH LIMITED

*K. Jagan Mohan*  
Managing Director





18	Reserves excluding revaluation reserve						
19	Debenture redemption reserve						
20	Earnings per share						
i	Earnings per equity share for continuing operations	1.54	0.52	0.30	2.06	0.49	1.30
	Basic earnings (loss) per share from continuing operations	1.54	0.52	0.30	2.06	0.49	1.30
	Diluted earnings (loss) per share from continuing operations						
ii	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations						
	Diluted earnings (loss) per share from discontinued operations						
iii	Earnings per equity share from continuing and discontinued operations	1.54	0.52	0.30	2.06	0.49	1.30
	Diluted earnings (loss) per share from continuing and discontinued operations	1.54	0.52	0.30	2.06	0.49	1.30

**Notes:**

1.The above Consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th November 2022 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared In accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2.The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website ([www.indrayani.com](http://www.indrayani.com)).

3.Figures for three months ended 30 September 2022 as reported in these financials results are the balancing figures between audited figures, in respect of the full previous year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subject to audit.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter.

5. Previous period figures have been regrouped wherever necessary.

Date : 14/11/2022  
Place : Chennai



For INDRAYANI BIOTECH LIMITED

*K. Jayaraj*  
Managing Director

**M/s. INDRAYANI BIOTECH LIMITED**  
**BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA**  
**INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032**

**CIN : L40100TN1992PLC129301**

**Unaudited Consolidated Statement of Assets & Liabilities**

<i>Particulars</i>	<i>Notes</i>	<i>30.09.2022</i>	<i>31.03.2022</i>
<b>ASSETS</b>			
<b>A) Non - Current Assets</b>			
a) Property Plant and Equipment	3	2,521.13	1,267.27
b) Capital Work in Progress	3	1,301.56	1,326.56
c) Goodwill	3	2,186.95	384.14
d) Other Intangible assets			
e) Financial Assets			
--- (i) Investments	4	0.05	0.05
--- (ii) Other Financial Assets		-	90.27
Non Current Tax Assets		34.04	112.75
Other Non Current assets	5	650.77	67.73
<b>B) Current Assets</b>			
a) Inventories	6	1,030.57	153.23
b) Financial Assets			
--- (i) Investments			
--- (ii) Trade Receivables	7	2,397.63	1,409.86
--- (iii) Cash and cash Equivalents	8	160.23	150.26
--- (iii) Other Financial Assets	9	282.30	49.67
c) Other Current assets	10	1,516.47	128.32
<b>Total Assets</b>		<b>12,081.70</b>	<b>5,140.11</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>A) Equity</b>			
a) Equity Share Capital	11	4,347.72	3,422.72
b) Other Equity	12	1,038.79	-1,006.38
b) Non Controlling Interest within Equity		-994.48	40.64
<b>B) LIABILITIES</b>			
<b>Non - Current Liabilities</b>			
a) Financial Liabilities			
--- (i) Borrowings	13	2,696.98	678.51
--- (ii) Other financial Liabilities			
--- (ii) Financial Lease Liabilities		35.44	55.00
b) Deferred Tax Liabilities	14	1.38	1.38
c) Other Non Current Liabilities			
<b>Current Liabilities</b>			
a) Financial Liabilities			
--- (i) Short Term Borrowings	15	2,172.32	1,110.27
--- (ii) Trade Payables			
----- (A) total outstanding dues of micro enterprises and small enterprises;			
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	16	2,404.85	582.00
--- (iii) Other financial Liabilities			
--- (ii) Financial Lease Liabilities		37.95	35.66
b) Other Current Liabilities	17	55.23	72.29
c) Provisions	18	285.52	148.02
<b>Total Equity &amp; Liabilities</b>		<b>12,081.70</b>	<b>5,140.11</b>

For INDRAYANI BIOTECH LIMITED

*K. Anjan*






**M/s. INDRAYANI BIOTECH LIMITED**  
**BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL**  
**ESTATE, GUINDY, CHENNAI, 600032**

**CIN : L40100TN1992PLC129301**

<b>Unaudited Consolidated Statement of Cash Flow</b>		<b>Amount in Rs. In Lakhs</b>	
<b>Particulars</b>	<b>As on 31-Sep-2022</b>	<b>As on 31-Mar-22</b>	
<b>Cash Flows From Operating Activities:-</b>			
Net Profit after Taxation	704.46	443.95	
<b>Adjustment for Non cash items</b>			
Add : Impairment of Fixed Assets	25.00		
Add : Depreciation	141.37	65.94	
Less : Interest Income Notional (As per Ind AS 109)	-2.88	-1.50	
Add : Notional Rent as per IND AS	1.53		
Less: Increase in Good will	-1,802.81		
<b>Adjustment for Non Operating activities</b>			
Add : Interest Paid	212.11	187.97	
Less : Interest Income	1.25		
<b>Cash Flow Before Working Capital changes:-</b>	<b>-719.97</b>	<b>696.36</b>	
Decrease (Increase) in Inventories	-877.34	-44.31	
Decrease (Increase) in Trade receivables	-987.77	-933.25	
Decrease (Increase) in other current assets	-1,620.78	-72.36	
(Decrease) Increase in Short term borrowings	1,062.05	369.46	
(Decrease) Increase in Lease Liabilities	2.29	35.66	
(Decrease) Increase in Trade payables	1,822.85	247.72	
(Decrease) Increase in Other Current liabilities	-17.06	53.93	
(Decrease) Increase in Provisions	137.50	57.89	
<b>Cash Flow Before Tax and Extraordinary Items:-</b>			
Income Taxes Paid		-	
<b>Net Cash Flow From Operating Activities</b>	<b>-1,198.22</b>	<b>411.10</b>	
<b>Cash Flow from Investing Activities:-</b>			
Less : Purchase of Capital Assets	-199.63	-118.91	
Less : Purchase of Investments	-733.48	-1.84	
Add : Rental Receipts			
Add : Amount of Interest Received			
Less : Sale of Capital Assets			
Decrease (Increase) in Loans and advances & Other assets	-414.06	64.94	
<b>Net Cash flow used in Investing Activities</b>	<b>-1,347.17</b>	<b>-55.81</b>	
<b>Cash Flow from Financing Activities:-</b>			
Increase in Borrowings	2,018.47		
Increase in Lease Liabilities	-19.56	55.00	
Interest Income Notional (As per Ind AS 109)	2.88	1.50	
Increase in Non Controlling Interest	-1,562.44	-4.61	
Increase in Share capital	925.00	-	
Share Premium collected	1,403.18	-	
Increase in Other Non current liabilities			
Interest expense	-212.11	-187.97	
Decrease in borrowings		-136.88	
<b>Net Cash Flow From Financing Activities</b>	<b>2,555.42</b>	<b>-272.96</b>	
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>			
(Opening Balance)	150.20	67.87	
Net Cash Flow during the year	10.03	82.33	
<b>(Closing Balance)</b>	<b>160.23</b>	<b>150.20</b>	

For INDRAYANI BIOTECH LIMITED

*K. Jeyaraj*  
Managing Director





**VENKATESH & CO**

Chartered Accountants

**Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To

The Board of Directors,

**Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended September 2022. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**for Venkatesh & Co**

Chartered Accountants

FRN : 004636S

**CA Dasaraty V**

Partner

M No : 026336

UDIN: 22026336BDBCES2027

Chennai, 14<sup>th</sup> November 2022



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai - 600 017.

Telefax : 2814 4763/64/65/66 Email : venkateshandco@gmail.com



**INDRAYANI BIOTECH LIMITED**

Regd. Office :

**BLOCK 1, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032**

SR No	STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER, 2022						
	Rs. In Lakhs						
	PARTICULARS	STANDALONE					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2022	30-Jun-22	30-09-2021	30-09-2022	30-09-2021	31-Mar-22
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	(a) Net Sales/Revenue from Operations	1,592.16	1,559.80	1,430.99	3,151.96	2,855.40	5,798.85
	(b) Other Income	6.18	38.24	3.70	44.42	6.23	22.08
	<b>Total Income from Operations</b>	<b>1,598.34</b>	<b>1,598.04</b>	<b>1,434.69</b>	<b>3,196.38</b>	<b>2,861.63</b>	<b>5,820.94</b>
2	<b>Expenses</b>						
	(a) Cost of Materials consumed	765.95	966.33	954.64	1,732.28	1,895.24	3,971.31
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-					
	(c) Employee benefits expenses	391.29	344.35	254.79	735.64	534.02	897.29
	(d) Finance Costs	56.73	39.03	52.90	95.76	85.14	187.97
	(e) Depreciation and amortisation expense	15.82	11.67	8.46	27.49	16.87	34.43
	(f) Other expenses	214.02	112.43	53.80	326.45	140.91	307.38
	<b>Total Expenses</b>	<b>1,443.81</b>	<b>1,473.81</b>	<b>1,324.59</b>	<b>2,917.62</b>	<b>2,672.18</b>	<b>5,398.38</b>
	<b>Total profit / (Loss) before exceptional items and tax</b>	<b>154.53</b>	<b>124.23</b>	<b>110.10</b>	<b>278.76</b>	<b>189.45</b>	<b>422.56</b>
3	<b>Exceptional Items</b>						
	Add: Share of Profit In Associates						
	Less: Written of CWIP	(25.00)			(25.00)		
5	<b>Total profit / (Loss) before tax</b>	<b>129.53</b>	<b>124.23</b>	<b>110.10</b>	<b>253.76</b>	<b>189.45</b>	<b>422.56</b>
6	<b>Total profit / (Loss) before tax</b>						
7	<b>Tax Expenses</b>						
	Current Tax						
	Deferred Tax						
	<b>Total Tax Expenses</b>						
8	<b>Net Profit Loss for the period from continuing operations</b>	<b>129.53</b>	<b>124.23</b>	<b>110.10</b>	<b>253.76</b>	<b>189.45</b>	<b>422.56</b>
9	<b>Profit (loss) from discontinued operations before tax</b>						
10	<b>Tax expense of discontinued operations</b>						
11	<b>Net profit (loss) from discontinued operation after tax</b>						
12	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>						
13	<b>Total profit (loss) for period</b>	<b>129.53</b>	<b>124.23</b>	<b>110.10</b>	<b>253.76</b>	<b>189.45</b>	<b>422.56</b>
14	<b>Other comprehensive income net of taxes</b>						
15	<b>Total Comprehensive income for the period attributable to</b>	<b>129.53</b>	<b>124.23</b>	<b>110.10</b>	<b>253.76</b>	<b>189.45</b>	<b>422.56</b>
	Comprehensive income for the period attributable to owners of parent	129.53	124.23	110.10	253.76	189.45	422.56
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests						
16	<b>Details of equity share capital</b>						
	<b>Paid-up equity share capital</b>	<b>3,422.72</b>	<b>3,422.72</b>	<b>3,422.72</b>	<b>3,422.72</b>	<b>3,422.72</b>	<b>3,422.72</b>
	<b>Face value of equity share capital(Rs.)</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>



For INDRAYANI BIOTECH LIMITED

*K. Jayanand*  
Managing Director

17	Details of debt securities						
	Paid-up debt capital						
	Face value of debt securities						
18	Reserves excluding revaluation reserve						
19	Debenture redemption reserve						
20	Earnings per share						
i	Earnings per equity share for continuing operations	0.38	0.36	0.32	0.74	0.55	1.23
	Basic earnings (loss) per share from continuing operations	0.38	0.36	0.32	0.74	0.55	1.23
	Diluted earnings (loss) per share from continuing operations						
ii	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations						
	Diluted earnings (loss) per share from discontinued operations						
iii	Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	0.38	0.36	0.32	0.74	0.55	1.23
	Diluted earnings (loss) per share from continuing and discontinued operations	0.38	0.36	0.32	0.74	0.55	1.23

**Notes:**

1. The above financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors Directors at their meeting held on 14th November 2022 and have been subjected to Limited review by the Statutory Auditors of the company. The above results have been prepared In accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website ([www.indrayani.com](http://www.indrayani.com)).
3. Figures for three months ended 30 September 2022 as reported in these financials results are the balancing figures between audited figures, in respect of the full previous year and the published year to date figures upto the third quarter of the previous financial year. The figures upto the end of the third quarter of previous financial year. The figures upto the end of the third quarter of previous financial year had only been reviewed and not subject to audit.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No compliants were received during the quarter.
5. Previous period figures have been regrouped wherever necessary.

Date : 14/11/2022  
Place : Chennai



For INDRAYANI BIOTECH LIMITED

*K. Jagan Mohan*  
Managing Director



<b>M/s. INDRAYANI BIOTECH LIMITED</b> <b>CIN : L40100TN1992PLC129301</b> <b>BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032</b>			
<b>Unaudited Standalone Statement of Assets and Liabilities</b>			
<b>Particulars</b>	<b>Notes</b>	<b>As at 30.09.2022</b>	<b>As at 31.03.2022</b>
<b>ASSETS</b>			
<b>A) Non - Current Assets</b>			
a) Property Plant and Equipment	3	1,221.58	1,149.39
c) Capital Work in Progress	3	1,296.96	1,321.96
d) Goodwill	3	383.53	383.53
e) Other Intangible assets			
f) Financial Assets			
--- (i) Investments	4	752.01	18.53
--- (ii) Other Financial Assets			
Non Current Tax Assets		90.27	90.27
Other Non Current Tax Assets		112.75	112.75
f) Other Non Current assets	5	522.16	67.73
<b>B) Current Assets</b>			
a) Inventories	6	230.97	136.55
b) Financial Assets			
--- (i) Investments			
--- (ii) Trade Receivables	7	2,154.67	1,287.64
--- (iii) Cash and cash Equivalents	8	115.17	144.52
--- (iii) Other Financial Assets	9	142.16	49.67
c) Other Current assets	10	1,205.63	180.92
<b>Total Assets</b>		<b>8,227.85</b>	<b>4,943.45</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>A) Equity</b>			
a) Equity Share Capital	11	4,347.72	3,422.72
b) Other Equity	12	651.79	-1,005.14
<b>B) LIABILITIES</b>			
<b>Non - Current Liabilities</b>			
a) Financial Liabilities			
--- (i) Borrowings	13	564.73	678.51
--- (ii) Other financial Liabilities			
b) Deferred Tax Liabilities	14	1.38	1.38
c) Other Non Current Liabilities			
<b>Current Liabilities</b>			
a) Financial Liabilities			
--- (i) Short Term Borrowings	15	1,862.09	994.84
--- (ii) Trade Payables			
----- (A) total outstanding dues of micro enterprises and small enterprises;			
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	16	620.27	644.93
--- (iii) Other financial Liabilities			
b) Other Current Liabilities	17	41.84	74.28
c) Provisions	18	138.02	131.94
<b>Total Equity &amp; Liabilities</b>		<b>8,227.85</b>	<b>4,943.44</b>

For INDRAYANI BIOTECH LIMITED

*K. Suresh Kumar*  
Managing Director



**M/s. INDRAYANI BIOTECH LIMITED**  
**BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL**  
**ESTATE, GUINDY, CHENNAI, 600032**

**CIN : L40100TN1992PLC129301**

<b>Unaudited Standalone Statement of Cash Flow</b>		
<b>Particulars</b>	<b>As on 30-Sep-22</b>	<b>Amount in Rs. As on 31-Mar-22</b>
<b>Cash Flows From Operating Activities:-</b>		
Net Profit after Taxation	253.76	422.56
<b>Adjustment for Non cash items</b>		
Add : Impairment of Fixed Assets	25.00	
Add : Depreciation	27.49	34.43
Less : Interest Income Notional (As per Ind AS 109)	-2.88	-1.50
Add : Notional Rent as per IND AS	1.53	
<b>Adjustment for Non Operating activities</b>		
Add : Interest Paid	95.76	187.97
Less : Interest income	-1.25	
<b>Cash Flow Before Working Capital changes:-</b>	<b>399.41</b>	<b>643.46</b>
Decrease (Increase) in Inventories	-94.42	-28.17
Decrease (Increase) in Trade receivables	-867.04	-810.83
Decrease (Increase) in other current assets	-1,118.73	-130.80
(Decrease) Increase in Short term borrowings	867.26	266.98
(Decrease) Increase in Trade payables	-24.66	302.82
(Decrease) Increase in Other Current liabilities	-32.43	56.15
(Decrease) Increase in Provisions	6.08	46.99
<b>Cash Flow Before Tax and Extraordinary Items:-</b>		
Income Taxes Paid		-
<b>Net Cash Flow From Operating Activities</b>	<b>-864.53</b>	<b>346.60</b>
<b>Cash Flow from Investing Activities:-</b>		
Less : Purchase of Capital Assets	-99.68	-6.31
Less : Purchase of Investments	-733.48	
Add : Rental Receipts		
Add : Amount of Interest Received		
Less : Sale of Capital Assets		
Decrease (Increase) in Loans and advances & Other assets	-454.43	64.94
<b>Net Cash flow used in Investing Activities</b>	<b>-1,287.59</b>	<b>58.63</b>
<b>Cash Flow from Financing Activities:-</b>		
Increase in Borrowings		
Interest Income Notional (As per Ind AS 109)	2.88	1.50
Increase in Share capital	925.00	
Share Premium collected	1,403.18	
Increase in Other Non current liabilities		
Interest expense	-95.76	-187.97
Decrease in borrowings	-112.53	-136.88
<b>Net Cash Flow From Financing Activities</b>	<b>2,122.77</b>	<b>-323.35</b>
<b>Net Increase/(Decrease) in Cash and Cash Equivalents:-</b>		
(Opening Balance)	144.53	62.65
Net Cash Flow during the year	-29.35	81.88
<b>(Closing Balance)</b>	<b>115.18</b>	<b>144.53</b>

For INDRAYANI BIOTECH LIMITED

*K. Jagan Mohan*  
Managing Director

